SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (34)11/2/2015 2:52:06 PM
From: scaram(o)uche  Respond to of 294
 
interesting.....

Proc Natl Acad Sci U S A. 2015 Oct 28. pii: 201520032. [Epub ahead of print]
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells.
Zhang H1, Lu H2, Xiang L2, Bullen JW2, Zhang C2, Samanta D2, Gilkes DM3, He J4, Semenza GL5.

  • 1Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China; Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
  • 2Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
  • 3Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205;
  • 4Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China;
  • 5Institute for Cell Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Radiation Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205; Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, MD 21205 gsemenza@jhmi.edu.

  • Increased expression of CD47 has been reported to enable cancer cells to evade phagocytosis by macrophages and to promote the cancer stem cell phenotype, but the molecular mechanisms regulating CD47 expression have not been determined. Here we report that hypoxia-inducible factor 1 (HIF-1) directly activates transcription of the CD47 gene in hypoxic breast cancer cells. Knockdown of HIF activity or CD47 expression increased the phagocytosis of breast cancer cells by bone marrow-derived macrophages. CD47 expression was increased in mammosphere cultures, which are enriched for cancer stem cells, and CD47 deficiency led to cancer stem cell depletion. Analysis of datasets derived from thousands of patients with breast cancer revealed that CD47 expression was correlated with HIF target gene expression and with patient mortality. Thus, CD47 expression contributes to the lethal breast cancer phenotype that is mediated by HIF-1.



    To: tuck who wrote (34)1/26/2016 12:30:05 PM
    From: tuck  Read Replies (2) | Respond to of 294
     
    >> I'm not seeing near term catalysts, so trading it technically.<<

    Link to trial: Trillium P1

    Final readout almost four years from now, but this is a two part trial, with P1a presumably reading out before the midpoint. I'd guess mid 2017. Perhaps management will provide a slightly more educated guess in the near future. They did say there would be an update this year, but whether that's just about enrollment progress or some sort of interim look, I'm not sure. Anyone?

    While there will be further preclinical activity, none of it looks like a big catalyst, unless 1) the stock is stupid oversold - umm, check - and a) really good preclinical combo data is revealed or b) they start solid tumor trial(s) earlier than market anticipates. The latter seems less likely near term, while blockbuster preclinical data - :>} - could come out at any time.

    First attempt at trading it technically not going well so far, but a small position.

    I am tempted to call up and ask if they are seeing any interest in their CD200 program, or if they are talking to anyone at all about it. They keep not talking about it publicly, so is it dead?

    Cheers, Tuck